Home | Business News | Browse by Publication | P | Pharma Marketletter

Serologicals enters product development accord with RheoGene.

Publication: Pharma Marketletter
Publication Date: 05-DEC-05
Format: Online
Delivery: Immediate Online Access

Article Excerpt
US drugmaker Serologicals Corp says that Chemicon International, its wholly-owned subsidiary based in Temecula, California, and genetic technology specialist RheoGene, have signed a semi-exclusive license to use the latter's RheoSwitch system and related technologies within Chemicon's research product lines focused on specialty research markets, including its growing stem cell...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Pharma Marketletter
Bausch & Lomb licenses anti-angiogenesis drugs from PTC.(PTC Therapeut..., December 05, 2005
Acambis starts Ph I study of C difficile vacc.(Acambis PLC, Clostridiu..., December 05, 2005
Xoma and Affitech agree antibody R&D deal.(Affitech USA Inc., research..., December 05, 2005
Cobra and Advaxis sign cancer vaccine deal.(Cobra Biomanufacturing PLC..., December 05, 2005
Biovail launches Glumetza in Canada.(hypoglycemic drug)(Brief Article), December 05, 2005

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.